Understanding Barriers to Adjuvant Therapy in Resected Non-small Cell Lung Cancer: A Multicenter Analysis
Open Access
- 6 October 2025
- journal article
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (10)
Abstract
Objectives: To investigate variables associated to not receiving adjuvant therapy in patients with resected pathological IB-IIIA non-small-cell lung cancer (NSCLC) from a national registry. Methods: Patients who had lung resections were analysed retrospectively for stages IB-III from 2009-2023, sourced from a multicenter registry. Uni/multivariable logistic regression was performed, and a predictive tool was created to predict adjuvant therapy probability and cut-off values were determined through receiver-operating characteristic curve (ROC). The model’s discrimination, performance, and fit were evaluated using area under the ROC curve (AUC-ROC), sensitivity/specificity, and Hosmer-Lemeshow test, respectively. Results: Of the 427 patients analysed, the mean age was 65.4 years, and 83.1% were treated under public insurance. Precisely, 38.4% of patients received adjuvant chemotherapy after surgery. Multivariable analysis identified older age (odds ratio [OR] = 1.06, P < 0.001), histological subtype (OR = 21.3, P < 0.001), public insurance (OR = 2.65, P = 0.006), stage I-B (OR = 8.10, P = 0.002), and negative lymph node status (OR = 3.34, P < 0.001) as independent factors associated with not receiving adjuvant therapy. Using the final equation, a calculated probability > 42.5% categorizes a patient for exclusive surgical intervention. The model’s performance yielded an AUC of 0.833, with a sensitivity of 90.2%. The Hosmer-Lemeshow test resulted in a P ≥ 0.05. Conclusions: Underutilization of adjuvant therapy in NSCLC is influenced by age, insurance type, and pathological factors. Public insurance status indicates healthcare access but does not fully capture social disparities. The absence of race, income, and geographic data limits broader analysis. Our model identifies patients at risk of treatment omission, aiding targeted interventions.Keywords
This publication has 26 references indexed in Scilit:
- High-risk features associated with recurrence in stage I lung adenocarcinomaThe Journal of Thoracic and Cardiovascular Surgery, 2024
- Association of socioeconomic factors with the receipt of neoadjuvant therapy for patients with non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2023
- The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2023
- Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialThe Lancet Oncology, 2022
- Quality of life in patients with malignant pleural effusion treated with an indwelling pleural catheter in an emerging countryClinics, 2022
- Video-Assisted Thoracoscopic or Open Lobectomy in Early-Stage Lung CancerNEJM Evidence, 2022
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialThe Lancet, 2021
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- Clinical-Pathologic Correlation and Guideline Concordance in Resectable Non-Small Cell Lung CancerThe Annals of Thoracic Surgery, 2019
- Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018